Methods of assessing the risk of clinical signs of hypersensitivity reaction to nucleoside antiviral compounds, including abacavir, are described. The methods include genotyping subjects for polymorphisms in the TNF.alpha. gene, the class 1 HLA genes, or a combination of both the TNF.alpha. and HLA genes.